Regentis Biomaterials Ltd.

About Regentis Biomaterials Ltd.

Regentis Biomaterials is a tissue repair company dedicated to developing and commercializing an innovative hydrogel platform for the repair of damaged tissue. Their vision is to create effective therapies that shorten recovery times and improve patients' quality of life, with a current focus on orthopedic treatments using resorbable hydrogel implants.

Products & Services

Gelrin Technology:A resorbable hydrogel implant platform for regenerating damaged or diseased tissue, particularly for orthopedic treatments. The manufacturing process meets strict international safety, quality, and biocompatibility standards, including GMP and ISO 13485.

Specialties

Tissue repair Hydrogel technology Orthopedic treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: IPO T: - FT: IPO	A: 10000000 MR: - FA: $10,000,000 FAN: 10000000	D: 2025-12-05 FD: 2025-12-05	1 investors
2	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 10000000 MR: - FA: $10,000,000 FAN: 10000000	D: 2025-12-03 FD: 2025-12-03	1 investors

IPO Latest

2025-12-05

$10.0M

1 investor (Pro only)

Initial Public Offering 2025-12-03

$10.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brian J. Cole

Professor in Orthopedics

R

Ron Arbel

CMO

E

Ehud Geller

Executive Chairman

J

Jeff Dykan

Managing Partner, SCP Vitalife

P

Pini Ben-Elazar

CEO of Mor Research Applications, Tech Transfer Office of Clalit Health Services

S

Susan Alpert

Principal

View 7 more team members with Pro

Unlock Full Team Directory

Recent News